Please ensure Javascript is enabled for purposes of website accessibility

GW Pharmaceuticals in 5 Charts

By Brian Orelli, PhD - Sep 22, 2016 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The marijuana-drug company has had quite the year.

GW Pharmaceuticals (GWPH) has come a long ways since gaining EU approval for Sativex, which treats muscle spasms in multiple sclerosis patients, but has been commercially disappointing with sales that would be a rounding error for many large biotechs. Here are five charts that show the current state of the biotech focused on making drugs from marijuana.

1. A rising stock price (by any way possible)

GWPH Chart

GWPH price data by YCharts

Like most biotechs, GW Phrmaceuticals had a rough second half of 2015 that continued into 2016 as investors left the sector for safer pastures. But GW Pharmaceuticals has been able to turn things around with a couple of nice spikes.

In March, the company reported positive data for its marijuana-derived drug, Epidiolex, in children with Dravet syndrome, a form of childhood epilepsy that's hard to treat.

And this month, GW Phamraceuitcals jumped again on word that the company might be up for sale.

2. Burning cash

GWPH Cash and Equivalents (Quarterly) Chart

GWPH Cash and Equivalents data by YCharts

Drug development isn't cheap, and GW Pharmaceuticals has been burning through cash quickly. Fortunately the chart above doesn't tell the full story as the company raised $273 million in July, which won't show up on the official balance sheet until it reports its fiscal fourth quarter earnings. With the proceeds from the secondary offering, GW Pharmaceuticals looks like it's in good shape to get its marketing application for Epidiolex submitted next year.

3. New drugs are needed

Image source: GW Pharmaceuticals.

Those data are from 2010, but not much has changed. Even today, 30% of epileptics are pharmacoresistant, meaning they still have seizures despite trying multiple medications. Obviously, developing drugs as a first-line therapy offers the largest opportunity, but GW Pharmaceuticals estimates there are about 140,000 patients in the U.S. that fit into the final-stage category, where the unmet need can justify higher pricing that can make up for the smaller market size.

4. Pipeline

Image source: GW Pharmaceuticals.

With multiple indications in later stages of development, most of GW Pharmaceuticals value is tied to Epidiolex, but the biotech does have other drugs in development.

In the fourth quarter, investors will get data from two of GW Pharmaceuticals' mid-stage drug candidates. Phase 2a data for a clinical trial testing GWP42002 and GWP42003 in patients with glioma, a type of brain cancer, will read out next quarter. Management has also guided to expect data for Sativex in patients with cerebral palsy in the fourth quarter.

GW Pharmaceuticals' GWP42006, which has a similar structure to Epidiolex, is currently in a phase 2 trial in epileptics. The biotech also plans to test GWP42006 in patients with autism spectrum disorders.

5. Positive data

Disease

Placebo (Reduction) in Seizure Frequency

Epidiolex (Reduction) in Seizure Frequency

Dravet Syndrome

(13%)

(39%)

Lennox-Gastaut Syndrome

(22%)

(44%)

Data source: GW Pharmaceuticals.

Dravet Syndrome and Lennox-Gastaut Syndrome are two hard-to-treat forms of childhood epilepsy, but Epidolex was able to reduce seizure frequency in both diseases compared to a placebo. The company is running another phase 3 trial in each of the indications. Assuming one or both of the clinical trials are positive, GW Pharmaceuticals will apply for a marketing application with the FDA next year.

Final Foolish thoughts

While there have been rumors that GW Pharmaceuticals is a buyout candidate -- and there have certainly been a lot of acquisitions in the sector lately -- it's ill-advised for investors to use that as their sole investment thesis. Fortunately, GW Pharmaceuticals has made substantial progress over the last year, making it worth considering as an investment even if the buyout doesn't happen.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.